Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GCG | P01275 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944437 | 0.95 | USP30 (0.43) | GPR119KDM4EPKMGCGHDAC4 | |
| SCHEMBL3635931 | 0.95 | USP30 (0.43) | GPR119KDM4EPKMGCGHDAC4 | |
| SCHEMBL3723766 | 0.86 | HDAC4 (0.54) | GPR119KDM4EPKMGCGLMNA | |
| SCHEMBL3723763 | 0.84 | ALDH1A1 (0.58) | GPR119 | |
| SCHEMBL3730320 | 0.83 | HDAC4 (0.55) | GCGADORA2AHDAC4 | |
| SCHEMBL4946424 | 0.83 | HDAC4 (0.55) | GCGADORA2AHDAC4 | |
| SCHEMBL3668808 | 0.81 | LMNA (0.49) | GPR119LMNATHRBPOLB | |
| SCHEMBL3730318 | 0.81 | ALDH1A1 (0.51) | GPR119 | |
| SCHEMBL3730316 | 0.81 | ALDH1A1 (0.51) | GPR119 | |
| SCHEMBL3672777 | 0.80 | USP30 (0.57) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | GPR119 655/4885KDM4E 1221/4885PKM 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.